Achieving Breakeven and Profitability
In Q4 2024, Precipio achieved positive adjusted EBITDA and positive cash flow, indicating a significant milestone towards profitability with a strong cash reserve and growth pipeline.
Revenue Growth
Precipio reported a revenue growth of nearly 26% in Q4 2024 compared to the previous year and a full-year revenue growth of close to 22%.
Pathology Division Performance
For the second consecutive quarter, pathology revenues exceeded the breakeven point of $1.3 million per month, with a target to reach a $25 million run rate by the end of 2025.
New Leadership in Products Division
Steve Miller rejoined as Chief Commercial Officer to drive growth in the products division, focusing on both direct sales and enhancing collaboration with distribution partners.